| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
NDRI National Disease Research Interchange is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Med-El Corporation is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carewell is an e-commerce company that provides home health products with discreet packaging and 24/7 service. They aim to improve the lives of caregivers and their loved ones by offering proactive service, compelling content, and expert-vetted products.
GRAND Mental Health is a nonprofit community behavioral health center that provides mental health care services to adults, children, and families in Northeast Oklahoma.